Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Centanni

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
Frontiers in Allergy|April 4, 2025
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE studyLuisa Brussino, Maria Aliani, Elena Altieri, et al.
Journal of Robotic Surgery|February 13, 2023
Impact of hands-on practice with HugoRAS and Versius System simulators on the attractiveness of robotic surgery among medical and nurse undergraduate studentsMaria Chiara Sighinolfi, Stefano Terzoni, Elena Scanferla, et al.
Journal of Asthma and Allergy|April 2, 2024
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE StudyPaolo Cameli, Maria Aliani, Elena Altieri, et al.
ERJ Open Research|February 18, 2026
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE studyGianenrico Senna, Luisa Brussino, Maria Aliani, et al.
The World Allergy Organization Journal|January 26, 2026
Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE studyGiorgio Walter Canonica, Gianenrico Senna, Luisa Brussino, et al.
Respiratory Research|May 20, 2023
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyAlessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Frontiers in Medicine|September 19, 2022
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study <i>post hoc</i> analysisCristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Journal of Clinical Medicine|July 31, 2020
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for CliniciansNicola Scichilone, Peter John Barnes, Salvatore Battaglia, et al.
European Urology Open Science|July 13, 2023
Prior Robotic Console Expertise May Improve Basic Skills at the New Hugo RAS Simulator: Results from a Cohort Trial and Implications for Skill Transference Across PlatformsMaria Chiara Sighinolfi, Stefano Terzoni, Elena Scanferla, et al.
Frontiers in Allergy|June 30, 2022
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study <i>post-hoc</i> AnalysisMaria D'Amato, Francesco Menzella, Elena Altieri, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Frontiers in Allergy|April 4, 2025
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE studyLuisa Brussino, Maria Aliani, Elena Altieri, et al.
Journal of Robotic Surgery|February 13, 2023
Impact of hands-on practice with HugoRAS and Versius System simulators on the attractiveness of robotic surgery among medical and nurse undergraduate studentsMaria Chiara Sighinolfi, Stefano Terzoni, Elena Scanferla, et al.
Journal of Asthma and Allergy|April 2, 2024
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE StudyPaolo Cameli, Maria Aliani, Elena Altieri, et al.
ERJ Open Research|February 18, 2026
Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE studyGianenrico Senna, Luisa Brussino, Maria Aliani, et al.
The World Allergy Organization Journal|January 26, 2026
Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE studyGiorgio Walter Canonica, Gianenrico Senna, Luisa Brussino, et al.
Respiratory Research|May 20, 2023
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE studyAlessandra Vultaggio, Maria Aliani, Elena Altieri, et al.
Frontiers in Medicine|September 19, 2022
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study <i>post hoc</i> analysisCristiano Caruso, Paolo Cameli, Elena Altieri, et al.
Journal of Clinical Medicine|July 31, 2020
The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for CliniciansNicola Scichilone, Peter John Barnes, Salvatore Battaglia, et al.
European Urology Open Science|July 13, 2023
Prior Robotic Console Expertise May Improve Basic Skills at the New Hugo RAS Simulator: Results from a Cohort Trial and Implications for Skill Transference Across PlatformsMaria Chiara Sighinolfi, Stefano Terzoni, Elena Scanferla, et al.
Frontiers in Allergy|June 30, 2022
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study <i>post-hoc</i> AnalysisMaria D'Amato, Francesco Menzella, Elena Altieri, et al.
Pageof 16